glp 1 gip agonists The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Targeting GLP-1, GIP & GCG
Description
doi: 10.2337/dci17-0057 [DOI] [PMC free article] [PubMed] [Google Scholar] 224
An autopsy study revealed a higher prevalence of coronary microvascular rarefaction, microscopic fibrosis, and hypertrophy in HFpEF patients [25]
Patent expiration dates for semaglutide and tirzepatide extend several years into the future, making FDA-approved generic versions unlikely until at least the late 2020s
Current understanding of the structure and function of family B GPCRs to design novel drugs
Trans R Soc Trop Med Hyg
The AAOS is the source of information on bone and joint conditions, treatments, and related musculoskeletal healthcare issues
